APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drug based on PARP Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Drug based on PARP Inhibitor Market Analysis and Forecast 2026-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchCancer Drug based on PARP Inhibitor Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drug based on PARP Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Cancer Drug based on PARP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drug based on PARP Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drug based on PARP Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Drug based on PARP Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cancer Drug based on PARP Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Drug based on PARP Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Drug based on PARP Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Drug based on PARP Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Cancer Drug based on PARP Inhibitor include Clovis Oncology, Zai Lab, AstraZeneca, GSK, Pfizer and Merck & Co, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cancer Drug based on PARP Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Drug based on PARP Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Cancer Drug based on PARP Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Drug based on PARP Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Drug based on PARP Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Cancer Drug based on PARP Inhibitor sales, projected growth trends, production technology, application and end-user industry.

Cancer Drug based on PARP Inhibitor Segment by Company

Clovis Oncology

Zai Lab

AstraZeneca

GSK

Pfizer

Merck & Co

Cancer Drug based on PARP Inhibitor Segment by Type

Talzenna

Rubraca

Zejula

Lynparza

Cancer Drug based on PARP Inhibitor Segment by Application

Ovarian Cancer

Breast Cancer

Other

Cancer Drug based on PARP Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drug based on PARP Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drug based on PARP Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drug based on PARP Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Cancer Drug based on PARP Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Cancer Drug based on PARP Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Drug based on PARP Inhibitor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Talzenna Major Manufacturers Table 3. Rubraca Major Manufacturers Table 4. Zejula Major Manufacturers Table 5. Lynparza Major Manufacturers Table 6. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Ovarian Cancer Major Manufacturers Table 8. Breast Cancer Major Manufacturers Table 9. Other Major Manufacturers Table 10. Cancer Drug based on PARP Inhibitor Industry Trends Table 11. Cancer Drug based on PARP Inhibitor Industry Drivers Table 12. Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges Table 13. Cancer Drug based on PARP Inhibitor Industry Restraints Table 14. Global Cancer Drug based on PARP Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2021-2026) Table 18. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2027-2032) Table 19. Global Cancer Drug based on PARP Inhibitor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026) & (K Units) Table 21. Global Cancer Drug based on PARP Inhibitor Sales by Region (2027-2032) & (K Units) Table 22. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2021-2026) Table 23. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2027-2032) Table 24. Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 28. Global Cancer Drug based on PARP Inhibitor Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Cancer Drug based on PARP Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Cancer Drug based on PARP Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Cancer Drug based on PARP Inhibitor Manufacturers, Product Type & Application Table 32. Global Cancer Drug based on PARP Inhibitor Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Cancer Drug based on PARP Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Cancer Drug based on PARP Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2021-2026) Table 39. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2027-2032) Table 40. Global Cancer Drug based on PARP Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 42. Global Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 43. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2021-2026) Table 44. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2027-2032) Table 45. Global Cancer Drug based on PARP Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 46. Global Cancer Drug based on PARP Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 47. Global Cancer Drug based on PARP Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2021-2026) Table 51. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2027-2032) Table 52. Global Cancer Drug based on PARP Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 54. Global Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 55. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2021-2026) Table 56. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2027-2032) Table 57. Global Cancer Drug based on PARP Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 58. Global Cancer Drug based on PARP Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 59. Clovis Oncology Company Information Table 60. Clovis Oncology Business Overview Table 61. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio Table 63. Clovis Oncology Recent Development Table 64. Zai Lab Company Information Table 65. Zai Lab Business Overview Table 66. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio Table 68. Zai Lab Recent Development Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio Table 73. AstraZeneca Recent Development Table 74. GSK Company Information Table 75. GSK Business Overview Table 76. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. GSK Cancer Drug based on PARP Inhibitor Product Portfolio Table 78. GSK Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio Table 83. Pfizer Recent Development Table 84. Merck & Co Company Information Table 85. Merck & Co Business Overview Table 86. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio Table 88. Merck & Co Recent Development Table 89. North America Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 90. North America Cancer Drug based on PARP Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 91. North America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 92. North America Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 93. North America Cancer Drug based on PARP Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 94. North America Cancer Drug based on PARP Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 95. North America Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 96. North America Cancer Drug based on PARP Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 97. North America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 98. North America Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 99. North America Cancer Drug based on PARP Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 100. North America Cancer Drug based on PARP Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 101. North America Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 103. North America Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 104. North America Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 105. North America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 106. North America Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 107. North America Cancer Drug based on PARP Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 108. North America Cancer Drug based on PARP Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 109. United States Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 110. Canada Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 111. Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 114. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 115. Europe Cancer Drug based on PARP Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 116. Europe Cancer Drug based on PARP Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 117. Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 120. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 121. Europe Cancer Drug based on PARP Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 122. Europe Cancer Drug based on PARP Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 123. Europe Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 125. Europe Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 126. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 127. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 128. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 129. Europe Cancer Drug based on PARP Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 130. Europe Cancer Drug based on PARP Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 131. Germany Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 132. France Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 133. U.K. Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 134. Italy Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 135. Netherlands Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 136. China Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 137. China Cancer Drug based on PARP Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 138. China Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 139. China Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 140. China Cancer Drug based on PARP Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 141. China Cancer Drug based on PARP Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 142. China Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 143. China Cancer Drug based on PARP Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 144. China Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 145. China Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 146. China Cancer Drug based on PARP Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 147. China Cancer Drug based on PARP Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 148. Asia Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 149. Asia Cancer Drug based on PARP Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 150. Asia Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 151. Asia Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 152. Asia Cancer Drug based on PARP Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 153. Asia Cancer Drug based on PARP Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 154. Asia Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 155. Asia Cancer Drug based on PARP Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 156. Asia Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 157. Asia Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 158. Asia Cancer Drug based on PARP Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 159. Asia Cancer Drug based on PARP Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 160. Asia Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Asia Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 162. Asia Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 163. Asia Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 164. Asia Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 165. Asia Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 166. Asia Cancer Drug based on PARP Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 167. Asia Cancer Drug based on PARP Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 168. Japan Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 169. South Korea Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 170. India Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 171. Australia Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 172. China Taiwan Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 173. Southeast Asia Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 174. SAMEA Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 175. SAMEA Cancer Drug based on PARP Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 176. SAMEA Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 177. SAMEA Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 178. SAMEA Cancer Drug based on PARP Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 179. SAMEA Cancer Drug based on PARP Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 180. SAMEA Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 181. SAMEA Cancer Drug based on PARP Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 182. SAMEA Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 183. SAMEA Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 184. SAMEA Cancer Drug based on PARP Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 185. SAMEA Cancer Drug based on PARP Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 186. SAMEA Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 187. SAMEA Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 188. SAMEA Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 189. SAMEA Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 190. SAMEA Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 191. SAMEA Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 192. SAMEA Cancer Drug based on PARP Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 193. SAMEA Cancer Drug based on PARP Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 194. Brazil Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 195. Argentina Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 196. Chile Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 197. Colombia Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 198. Peru Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 199. Saudi Arabia Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 200. Israel Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 201. UAE Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 202. Turkey Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 203. Iran Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 204. Egypt Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Table 205. Key Raw Materials Table 206. Raw Materials Key Suppliers Table 207. Cancer Drug based on PARP Inhibitor Distributors List Table 208. Cancer Drug based on PARP Inhibitor Customers List Table 209. Research Programs/Design for This Report Table 210. Authors List of This Report Table 211. Secondary Sources Table 212. Primary Sources List of Figures Figure 1. Cancer Drug based on PARP Inhibitor Image Figure 2. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drug based on PARP Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Talzenna Image Figure 5. Rubraca Image Figure 6. Zejula Image Figure 7. Lynparza Image Figure 8. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Cancer Drug based on PARP Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 10. Ovarian Cancer Image Figure 11. Breast Cancer Image Figure 12. Other Image Figure 13. Global Cancer Drug based on PARP Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 15. Global Cancer Drug based on PARP Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2021-2032) Figure 18. Global Cancer Drug based on PARP Inhibitor Sales (2021-2032) & (K Units) Figure 19. Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Cancer Drug based on PARP Inhibitor Sales YoY (2021-2032) & (K Units) Figure 22. Europe Cancer Drug based on PARP Inhibitor Sales YoY (2021-2032) & (K Units) Figure 23. China Cancer Drug based on PARP Inhibitor Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Cancer Drug based on PARP Inhibitor Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales YoY (2021-2032) & (K Units) Figure 26. Global Cancer Drug based on PARP Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Cancer Drug based on PARP Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2021-2032) Figure 32. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2021-2032) Figure 35. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2021-2032) Figure 38. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2021-2032) Figure 41. North America Cancer Drug based on PARP Inhibitor Revenue Share by Type (2021-2032) Figure 42. North America Cancer Drug based on PARP Inhibitor Sales Share by Type (2021-2032) Figure 43. North America Cancer Drug based on PARP Inhibitor Revenue Share by Application (2021-2032) Figure 44. North America Cancer Drug based on PARP Inhibitor Sales Share by Application (2021-2032) Figure 45. North America Cancer Drug based on PARP Inhibitor Revenue Share by Country (2021-2032) Figure 46. North America Cancer Drug based on PARP Inhibitor Sales Share by Country (2021-2032) Figure 47. Europe Cancer Drug based on PARP Inhibitor Revenue Share by Type (2021-2032) Figure 48. Europe Cancer Drug based on PARP Inhibitor Sales Share by Type (2021-2032) Figure 49. Europe Cancer Drug based on PARP Inhibitor Revenue Share by Application (2021-2032) Figure 50. Europe Cancer Drug based on PARP Inhibitor Sales Share by Application (2021-2032) Figure 51. Europe Cancer Drug based on PARP Inhibitor Revenue Share by Country (2021-2032) Figure 52. Europe Cancer Drug based on PARP Inhibitor Sales Share by Country (2021-2032) Figure 53. China Cancer Drug based on PARP Inhibitor Revenue Share by Type (2021-2032) Figure 54. China Cancer Drug based on PARP Inhibitor Sales Share by Type (2021-2032) Figure 55. China Cancer Drug based on PARP Inhibitor Revenue Share by Application (2021-2032) Figure 56. China Cancer Drug based on PARP Inhibitor Sales Share by Application (2021-2032) Figure 57. Asia Cancer Drug based on PARP Inhibitor Revenue Share by Type (2021-2032) Figure 58. Asia Cancer Drug based on PARP Inhibitor Sales Share by Type (2021-2032) Figure 59. Asia Cancer Drug based on PARP Inhibitor Revenue Share by Application (2021-2032) Figure 60. Asia Cancer Drug based on PARP Inhibitor Sales Share by Application (2021-2032) Figure 61. Asia Cancer Drug based on PARP Inhibitor Revenue Share by Country (2021-2032) Figure 62. Asia Cancer Drug based on PARP Inhibitor Sales Share by Country (2021-2032) Figure 63. SAMEA Cancer Drug based on PARP Inhibitor Revenue Share by Type (2021-2032) Figure 64. SAMEA Cancer Drug based on PARP Inhibitor Sales Share by Type (2021-2032) Figure 65. SAMEA Cancer Drug based on PARP Inhibitor Revenue Share by Application (2021-2032) Figure 66. SAMEA Cancer Drug based on PARP Inhibitor Sales Share by Application (2021-2032) Figure 67. SAMEA Cancer Drug based on PARP Inhibitor Revenue Share by Country (2021-2032) Figure 68. SAMEA Cancer Drug based on PARP Inhibitor Sales Share by Country (2021-2032) Figure 69. Cancer Drug based on PARP Inhibitor Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Cancer Drug based on PARP Inhibitor Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Talzenna
  • Rubraca
  • Zejula
  • Lynparza
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • Clovis Oncology
  • Zai Lab
  • AstraZeneca
  • GSK
  • Pfizer
  • Merck & Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Drug based on PARP Inhibitor Market by Type
  3. 1.2.1 Global Cancer Drug based on PARP Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Talzenna
  5. 1.2.3 Rubraca
  6. 1.2.4 Zejula
  7. 1.2.5 Lynparza
  8. 1.3 Cancer Drug based on PARP Inhibitor Market by Application
  9. 1.3.1 Global Cancer Drug based on PARP Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Ovarian Cancer
  11. 1.3.3 Breast Cancer
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Cancer Drug based on PARP Inhibitor Market Dynamics
  1. 2.1 Cancer Drug based on PARP Inhibitor Industry Trends
  2. 2.2 Cancer Drug based on PARP Inhibitor Industry Drivers
  3. 2.3 Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges
  4. 2.4 Cancer Drug based on PARP Inhibitor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Cancer Drug based on PARP Inhibitor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region
  3. 3.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2021-2026)
  5. 3.2.3 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2027-2032)
  6. 3.2.4 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Cancer Drug based on PARP Inhibitor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Cancer Drug based on PARP Inhibitor Sales by Region
  9. 3.4.1 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026)
  11. 3.4.3 Global Cancer Drug based on PARP Inhibitor Sales by Region (2027-2032)
  12. 3.4.4 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers
  2. 4.1.1 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Cancer Drug based on PARP Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers
  6. 4.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Cancer Drug based on PARP Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Cancer Drug based on PARP Inhibitor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Cancer Drug based on PARP Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Cancer Drug based on PARP Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Cancer Drug based on PARP Inhibitor Manufacturers, Product Type & Application
  13. 4.7 Global Cancer Drug based on PARP Inhibitor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Cancer Drug based on PARP Inhibitor Market CR5 and HHI
  16. 4.8.2 2025 Cancer Drug based on PARP Inhibitor Tier 1, Tier 2, and Tier 3
5 Cancer Drug based on PARP Inhibitor Market by Type
  1. 5.1 Global Cancer Drug based on PARP Inhibitor Revenue by Type
  2. 5.1.1 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Cancer Drug based on PARP Inhibitor Sales by Type
  6. 5.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Drug based on PARP Inhibitor Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2021-2032)
  9. 5.3 Global Cancer Drug based on PARP Inhibitor Price by Type
6 Cancer Drug based on PARP Inhibitor Market by Application
  1. 6.1 Global Cancer Drug based on PARP Inhibitor Revenue by Application
  2. 6.1.1 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Cancer Drug based on PARP Inhibitor Sales by Application
  6. 6.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Cancer Drug based on PARP Inhibitor Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2021-2032)
  9. 6.3 Global Cancer Drug based on PARP Inhibitor Price by Application
7 Company Profiles
  1. 7.1 Clovis Oncology
  2. 7.1.1 Clovis Oncology Company Information
  3. 7.1.2 Clovis Oncology Business Overview
  4. 7.1.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio
  6. 7.1.5 Clovis Oncology Recent Developments
  7. 7.2 Zai Lab
  8. 7.2.1 Zai Lab Company Information
  9. 7.2.2 Zai Lab Business Overview
  10. 7.2.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio
  12. 7.2.5 Zai Lab Recent Developments
  13. 7.3 AstraZeneca
  14. 7.3.1 AstraZeneca Company Information
  15. 7.3.2 AstraZeneca Business Overview
  16. 7.3.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio
  18. 7.3.5 AstraZeneca Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GSK Cancer Drug based on PARP Inhibitor Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Merck & Co
  32. 7.6.1 Merck & Co Company Information
  33. 7.6.2 Merck & Co Business Overview
  34. 7.6.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio
  36. 7.6.5 Merck & Co Recent Developments
8 North America
  1. 8.1 North America Cancer Drug based on PARP Inhibitor Market Size by Type
  2. 8.1.1 North America Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2032)
  3. 8.1.2 North America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2032)
  4. 8.1.3 North America Cancer Drug based on PARP Inhibitor Price by Type (2021-2032)
  5. 8.2 North America Cancer Drug based on PARP Inhibitor Market Size by Application
  6. 8.2.1 North America Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2032)
  7. 8.2.2 North America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2032)
  8. 8.2.3 North America Cancer Drug based on PARP Inhibitor Price by Application (2021-2032)
  9. 8.3 North America Cancer Drug based on PARP Inhibitor Market Size by Country
  10. 8.3.1 North America Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Cancer Drug based on PARP Inhibitor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Cancer Drug based on PARP Inhibitor Market Size by Type
  2. 9.1.1 Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2032)
  3. 9.1.2 Europe Cancer Drug based on PARP Inhibitor Sales by Type (2021-2032)
  4. 9.1.3 Europe Cancer Drug based on PARP Inhibitor Price by Type (2021-2032)
  5. 9.2 Europe Cancer Drug based on PARP Inhibitor Market Size by Application
  6. 9.2.1 Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2032)
  7. 9.2.2 Europe Cancer Drug based on PARP Inhibitor Sales by Application (2021-2032)
  8. 9.2.3 Europe Cancer Drug based on PARP Inhibitor Price by Application (2021-2032)
  9. 9.3 Europe Cancer Drug based on PARP Inhibitor Market Size by Country
  10. 9.3.1 Europe Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Cancer Drug based on PARP Inhibitor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Cancer Drug based on PARP Inhibitor Market Size by Type
  2. 10.1.1 China Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2032)
  3. 10.1.2 China Cancer Drug based on PARP Inhibitor Sales by Type (2021-2032)
  4. 10.1.3 China Cancer Drug based on PARP Inhibitor Price by Type (2021-2032)
  5. 10.2 China Cancer Drug based on PARP Inhibitor Market Size by Application
  6. 10.2.1 China Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2032)
  7. 10.2.2 China Cancer Drug based on PARP Inhibitor Sales by Application (2021-2032)
  8. 10.2.3 China Cancer Drug based on PARP Inhibitor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Drug based on PARP Inhibitor Market Size by Type
  2. 11.1.1 Asia Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2032)
  3. 11.1.2 Asia Cancer Drug based on PARP Inhibitor Sales by Type (2021-2032)
  4. 11.1.3 Asia Cancer Drug based on PARP Inhibitor Price by Type (2021-2032)
  5. 11.2 Asia Cancer Drug based on PARP Inhibitor Market Size by Application
  6. 11.2.1 Asia Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2032)
  7. 11.2.2 Asia Cancer Drug based on PARP Inhibitor Sales by Application (2021-2032)
  8. 11.2.3 Asia Cancer Drug based on PARP Inhibitor Price by Application (2021-2032)
  9. 11.3 Asia Cancer Drug based on PARP Inhibitor Market Size by Country
  10. 11.3.1 Asia Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Cancer Drug based on PARP Inhibitor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Drug based on PARP Inhibitor Market Size by Type
  2. 12.1.1 SAMEA Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Cancer Drug based on PARP Inhibitor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Cancer Drug based on PARP Inhibitor Price by Type (2021-2032)
  5. 12.2 SAMEA Cancer Drug based on PARP Inhibitor Market Size by Application
  6. 12.2.1 SAMEA Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Cancer Drug based on PARP Inhibitor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Cancer Drug based on PARP Inhibitor Price by Application (2021-2032)
  9. 12.3 SAMEA Cancer Drug based on PARP Inhibitor Market Size by Country
  10. 12.3.1 SAMEA Cancer Drug based on PARP Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Cancer Drug based on PARP Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Cancer Drug based on PARP Inhibitor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Cancer Drug based on PARP Inhibitor Value Chain Analysis
  2. 13.1.1 Cancer Drug based on PARP Inhibitor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Cancer Drug based on PARP Inhibitor Production Mode & Process
  6. 13.2 Cancer Drug based on PARP Inhibitor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Cancer Drug based on PARP Inhibitor Distributors
  9. 13.2.3 Cancer Drug based on PARP Inhibitor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst